Shiloh
Editor, Senior Moderator
Source: http://health.usnews.com/health-new.../new-drug-combo-for-hepatitis-c-shows-promise
New Drug Combo for Hepatitis C Shows Promise
Called 'watershed' research, study reports success with oral meds
January 18, 2012 RSS Feed Print
By Mary Brophy Marcus
HealthDay Reporter
WEDNESDAY, Jan. 18 (HealthDay News) -- A new cocktail of two investigational drugs appears to have successfully cleared the hepatitis C virus in people who don't respond to standard treatment.
What's more, the approach seems to work without the need for injections with interferon alpha, an onerous medication that causes serious side effects in many patients.
Scientists from seven U.S. medical centers and drug maker Bristol-Myers Squibb published the small study in the Jan. 19 issue of the New England Journal of Medicine that is being heralded as "landmark" research...
**************************
Source: http://www.marketwatch.com/story/fi...g-antiviral-only-therapy-published-2012-01-18
press release
Jan. 18, 2012, 5:01 p.m. EST
First Hepatitis C Treatment Data Demonstrating Proof of Principle with Direct-Acting Antiviral-only Therapy Published
Study also Demonstrated 100% Sustained Virologic Response 12-Weeks Post Treatment with Quadruple Therapy
PRINCETON, N.J., Jan 18, 2012 (BUSINESS WIRE) -- --Phase II Investigational Data Published Today in the New England Journal of Medicine
Bristol-Myers Squibb Company /quotes/zigman/220498/quotes/nls/bmy BMY -0.06% today announced the full results, published in the New England Journal of Medicine, from a Phase II clinical trial in patients with hepatitis C virus (HCV) genotype 1 who had not responded to prior therapy with PEG-interferon alfa and ribavirin ('null responders'(1)). The study demonstrated that its primary endpoint of the achievement of sustained virologic response 12-weeks post-treatment (SVR12) is possible with a direct-acting antiviral (DAA)-only combination containing daclatasvir and asunaprevir (4/11 patients, including two of two patients infected with HCV genotype 1b). This study was the first study to demonstrate the possibility that hepatitis C can be cured (defined as sustained virologic response 48 weeks post-treatment or SVR48) without the use of interferon. The study also demonstrated that 100 percent (10/10) of these difficult-to-treat patients dosed with quadruple therapy containing daclatasvir and asunaprevir in combination with PEG-Interferon alfa and ribavirin achieved SVR12...
New Drug Combo for Hepatitis C Shows Promise
Called 'watershed' research, study reports success with oral meds
January 18, 2012 RSS Feed Print
By Mary Brophy Marcus
HealthDay Reporter
WEDNESDAY, Jan. 18 (HealthDay News) -- A new cocktail of two investigational drugs appears to have successfully cleared the hepatitis C virus in people who don't respond to standard treatment.
What's more, the approach seems to work without the need for injections with interferon alpha, an onerous medication that causes serious side effects in many patients.
Scientists from seven U.S. medical centers and drug maker Bristol-Myers Squibb published the small study in the Jan. 19 issue of the New England Journal of Medicine that is being heralded as "landmark" research...
**************************
Source: http://www.marketwatch.com/story/fi...g-antiviral-only-therapy-published-2012-01-18
press release
Jan. 18, 2012, 5:01 p.m. EST
First Hepatitis C Treatment Data Demonstrating Proof of Principle with Direct-Acting Antiviral-only Therapy Published
Study also Demonstrated 100% Sustained Virologic Response 12-Weeks Post Treatment with Quadruple Therapy
PRINCETON, N.J., Jan 18, 2012 (BUSINESS WIRE) -- --Phase II Investigational Data Published Today in the New England Journal of Medicine
Bristol-Myers Squibb Company /quotes/zigman/220498/quotes/nls/bmy BMY -0.06% today announced the full results, published in the New England Journal of Medicine, from a Phase II clinical trial in patients with hepatitis C virus (HCV) genotype 1 who had not responded to prior therapy with PEG-interferon alfa and ribavirin ('null responders'(1)). The study demonstrated that its primary endpoint of the achievement of sustained virologic response 12-weeks post-treatment (SVR12) is possible with a direct-acting antiviral (DAA)-only combination containing daclatasvir and asunaprevir (4/11 patients, including two of two patients infected with HCV genotype 1b). This study was the first study to demonstrate the possibility that hepatitis C can be cured (defined as sustained virologic response 48 weeks post-treatment or SVR48) without the use of interferon. The study also demonstrated that 100 percent (10/10) of these difficult-to-treat patients dosed with quadruple therapy containing daclatasvir and asunaprevir in combination with PEG-Interferon alfa and ribavirin achieved SVR12...